A potential 100% tariff on drugmakers without pricing deals has surfaced, with an announcement timeline as soon as Thursday. The prospect is dragging Pfizer sentiment and represents a significant regulatory risk that could materially pressure pharma revenues, profits and sector valuations if enacted.
A potential 100% tariff on drugmakers without pricing deals has surfaced, with an announcement timeline as soon as Thursday. The prospect is dragging Pfizer sentiment and represents a significant regulatory risk that could materially pressure pharma revenues, profits and sector valuations if enacted.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly negative
Sentiment Score
-0.65
Ticker Sentiment
